Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Safety profile of recombinant canarypox HIV vaccines
Vaccine, Volume 22, No. 5-6, Year 2004
Notification
URL copied to clipboard!
Description
Attenuated poxviruses have been developed for use as candidate vaccine vectors. ALVAC, a strain of the Avipoxvirus canarypox, has been extensively evaluated as a vector for vaccines against the human immunodeficiency virus type 1 (HIV-1). This report presents the safety and reactogenicity data derived from 11 multicenter, randomized controlled trials of ALVAC-HIV vaccines conducted by the HIV Vaccine Trials Network (HVTN) and its predecessor, the AIDS Vaccine Evaluation Group (AVEG). Five different ALVAC vaccine constructs were tested among 1497 volunteers. Reactogenicity was similar for different ALVAC constructs. Local reactions of any grade to ALVAC vaccines were common. However, fewer than 2% of vaccinees had severe local responses, and less than 1% experienced severe local pain or tenderness. Systemic responses were mild and transient. As combination vaccine regimens are in common use, we also evaluated side effects of ALVAC vectors given in combination with a recombinant subunit protein. No significant differences were noted in the reactogenicity of ALVAC given with or without a recombinant envelope subunit vaccine. Black, non-Hispanic and male recipients of ALVAC-HIV reported less pain following vaccination than White, non-Hispanics and females, respectively. ALVAC-HIV vaccines are well tolerated at tested doses. The reactogenicity profiles are comparable to those reported for existing vaccines licensed for use among adults. Reactogenicity does not appear to be related to the number or type of inserted genes, and did not vary between different ALVAC constructs. © 2003 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
De Bruyn, Guy
United States, Seattle
Fred Hutchinson Cancer Center
Chiu, Yalin
United States, Seattle
Fred Hutchinson Cancer Center
Elizaga, Marnie L.
United States, Seattle
University of Washington
Burke, Donald S.
United States, Baltimore
Johns Hopkins University
Evans, Thomas George
United States, Rochester
University of Rochester Medical Center
United States, San Diego
Vical
Corey, Lawrence
United States, Seattle
Fred Hutchinson Cancer Center
Keefer, Michael C.
United States, Rochester
University of Rochester Medical Center
Statistics
Citations: 63
Authors: 7
Affiliations: 6
Identifiers
Doi:
10.1016/j.vaccine.2003.08.023
ISSN:
0264410X
Research Areas
Infectious Diseases
Participants Gender
Male
Female